Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.79% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2276
Airgain
AIRG
$55.3M
| $1.53M | ﹤0.01% |
366,736
-23,900
| -6% | -$94.1K |
2019 Q1
25 quarters
|
|
2277
Vermilion Energy
VET
$1.87B
| $1.53M | ﹤0.01% |
210,500
+76,900
| +58% | +$525K |
2024 Q4
2 quarters
|
|
2278
Schwab US TIPS ETF
SCHP
$16.2B
| $1.53M | ﹤0.01% |
57,400
-117,800
| -67% | -$3.12M |
2024 Q2
4 quarters
|
|
2279
Everspin Technologies
MRAM
$367M
| $1.53M | ﹤0.01% |
243,267
+5,800
| +2% | +$32.8K |
2020 Q1
21 quarters
|
|
2280
Malibu Boats
MBUU
$432M
| $1.53M | ﹤0.01% |
48,700
+12,500
| +35% | +$376K |
2015 Q2
40 quarters
|
|
2281
Agora
API
$374M
| $1.52M | ﹤0.01% |
399,100
-56,300
| -12% | -$196K |
2021 Q4
14 quarters
|
|
2282
AGF US Market Neutral Anti-Beta Fund
BTAL
$318M
| $1.52M | ﹤0.01% |
85,680
+27,949
| +48% | +$544K |
2024 Q3
3 quarters
|
|
2283
Stoneridge
SRI
$174M
| $1.52M | ﹤0.01% |
215,300
+119,600
| +125% | +$586K |
2024 Q3
3 quarters
|
|
2284
High Tide
HITI
$230M
| $1.52M | ﹤0.01% |
658,956
+130,656
| +25% | +$293K |
2023 Q2
8 quarters
|
|
2285
iShares U.S. Thematic Rotation Active ETF
THRO
$7.51B
| $1.51M | ﹤0.01% |
+42,500
| New | +$1.4M |
2025 Q2
0 quarters
|
|
2286
Palvella Therapeutics
PVLA
$1.85B
| $1.51M | ﹤0.01% |
66,858
+51,600
| +338% | +$1.21M |
2017 Q1
33 quarters
|
|
2287
Atossa Therapeutics
ATOS
$25.5M
| $1.5M | ﹤0.01% |
120,817
-2,856
| -2% | -$34.1K |
2021 Q4
14 quarters
|
|
2288
United-Guardian
UG
$31.5M
| $1.5M | ﹤0.01% |
187,963
-1,000
| -0.5% | -$8.27K |
2013 Q2
48 quarters
|
|
2289
IDEX
IEX
$17.5B
| $1.5M | ﹤0.01% |
+8,525
| New | +$1.51M |
2025 Q2
0 quarters
|
|
2290
Americas Gold and Silver
USAS
$1.36B
| $1.49M | ﹤0.01% |
740,000
+116,097
| +19% | +$187K |
2022 Q4
10 quarters
|
|
2291
DELISTED
Akero Therapeutics
AKRO
| $1.49M | ﹤0.01% |
28,000
-171,000
| -86% | -$7.77M |
2024 Q4
2 quarters
|
|
2292
Saga Communications
SGA
$51.5M
| $1.49M | ﹤0.01% |
114,644
-1,600
| -1% | -$19.2K |
2013 Q2
48 quarters
|
|
2293
VictoryShares Free Cash Flow ETF
VFLO
$11.5B
| $1.48M | ﹤0.01% |
42,000
-103,700
| -71% | -$3.49M |
2024 Q4
2 quarters
|
|
2294
PDF Solutions
PDFS
$2.01B
| $1.48M | ﹤0.01% |
69,300
+16,500
| +31% | +$312K |
2024 Q3
3 quarters
|
|
2295
USCB Financial Holdings
USCB
$409M
| $1.48M | ﹤0.01% |
89,306
-6,536
| -7% | -$110K |
2021 Q4
14 quarters
|
|
2296
Data I/O
DAIO
$29.5M
| $1.48M | ﹤0.01% |
476,343
-3,272
| -0.7% | -$8.24K |
2013 Q2
48 quarters
|
|
2297
CAE Inc
CAE
$7.55B
| $1.48M | ﹤0.01% |
50,400
-31,700
| -39% | -$799K |
2025 Q1
1 quarter
|
|
2298
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$553M
| $1.47M | ﹤0.01% |
+25,900
| New | +$1.37M |
2025 Q2
0 quarters
|
|
2299
Eagle Bancorp Montana
EBMT
$166M
| $1.47M | ﹤0.01% |
88,410
+9,661
| +12% | +$162K |
2016 Q4
34 quarters
|
|
2300
Instil Bio
TIL
$41.9M
| $1.47M | ﹤0.01% |
70,655
-34,288
| -33% | -$717K |
2022 Q4
10 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.